Nicotine therapeutic benefits: Difference between revisions

Line 1,030:

*[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version]

**Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631.

===2007: [https://pmc.ncbi.nlm.nih.gov/articles/PMC2702723/ Nicotinic Interactions with Antipsychotic Drugs, Models of Schizophrenia and Impacts on Cognitive Function]===

*Human and Animal study

*Nicotinic receptor systems in the brain are important for a variety of aspects of cognitive function impaired in schizophrenia and aggravated by antipsychotic drugs. Nicotine and selective nicotinic α7 and α4β2 agonists can significantly improve learning, memory and attention. Nicotine and nicotine agonists can reduce some of the cognitive impairments caused by some antipsychotic drugs as well as reduce cognitive impairments seen in the NMDA glutamate blockade animal model of schizophrenia.

**Citation: Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007 Oct 15;74(8):1182-91. doi: 10.1016/j.bcp.2007.07.019. Epub 2007 Jul 20. PMID: 17714691; PMCID: PMC2702723.

***Acknowledgement: Research presented was supported by a grant from the National Institute of Mental Health grant MH64494.

===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===

@@ Line 1,030: / Line 1,030: @@
 *[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version]
 **Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631.
+===2007: [https://pmc.ncbi.nlm.nih.gov/articles/PMC2702723/ Nicotinic Interactions with Antipsychotic Drugs, Models of Schizophrenia and Impacts on Cognitive Function]===
+*Human and Animal study
+*Nicotinic receptor systems in the brain are important for a variety of aspects of cognitive function impaired in schizophrenia and aggravated by antipsychotic drugs. Nicotine and selective nicotinic α7 and α4β2 agonists can significantly improve learning, memory and attention. Nicotine and nicotine agonists can reduce some of the cognitive impairments caused by some antipsychotic drugs as well as reduce cognitive impairments seen in the NMDA glutamate blockade animal model of schizophrenia.
+**Citation: Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007 Oct 15;74(8):1182-91. doi: 10.1016/j.bcp.2007.07.019. Epub 2007 Jul 20. PMID: 17714691; PMCID: PMC2702723.
+***Acknowledgement: Research presented was supported by a grant from the National Institute of Mental Health grant MH64494.
 ===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===